Imigran (Sumatriptan)

Sumatriptan is a selective agonist of serotonin 5‑HT1B and 5‑HT1D receptors located on intracranial blood vessels and trigeminal nerve endings. Activation of these receptors causes cranial vasoconstriction and inhibits the release of pro‑inflammatory neuropeptides, thereby reducing migraine pain and associated symptoms.

The prescribed dose of Imigran nasal spray is determined by the treating physician based on the individual’s clinical response and medical history. Typically, a single 20 mg spray may be administered at the onset of a migraine, with a second dose allowed after a specified interval if needed, but exact dosing must follow the prescriber’s instructions.

The safety of sumatriptan during pregnancy has not been conclusively established, and it is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk to the fetus. Caution is also advised during breastfeeding, as the drug can be excreted in milk; a healthcare professional should evaluate the risk‑benefit ratio.

To place an order, submit an enquiry on the Imigran product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details, and assists with any necessary import documentation.

Imigran belongs to the triptan class, which is generally more specific for migraine than non‑specific analgesics such as NSAIDs. Compared with oral sumatriptan tablets, the nasal spray offers a faster onset of action and may be preferable for patients with nausea or vomiting. However, other triptans or newer CGRP antagonists may be chosen based on individual response, tolerability, and physician preference.

Imigran nasal spray should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not expose the device to extreme heat or freeze it. Keep the spray away from children and ensure the cap is securely closed when not in use.

The nasal spray is administered by inserting the tip into one nostril, tilting the head slightly forward, and pressing the actuator to deliver a single 20 mg spray. The patient should breathe gently through the nose during administration and avoid blowing the nose for several minutes afterward. If additional dosing is required, follow the prescriber’s guidance regarding timing and maximum daily dose.

Serious adverse events, although rare, can include chest discomfort or tightness, coronary vasospasm, severe hypertension, and serotonin syndrome, especially when combined with other serotonergic drugs. Patients experiencing any cardiovascular symptoms or signs of an allergic reaction should seek immediate medical attention. Monitoring for these risks is essential, particularly in individuals with pre‑existing heart disease.

Imigran is contraindicated in patients with a history of coronary artery disease, uncontrolled hypertension, peripheral vascular disease, or cerebrovascular disorders. It should also be avoided in individuals who have experienced a previous myocardial infarction, stroke, or hemiplegic migraine. Patients taking monoamine oxidase inhibitors, other triptans, or ergot derivatives should not use Imigran without medical supervision.